REVIEW
|
doi:10.20944/preprints201810.0577.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
myeloma; daratumumab; elotuzumab; isatuximab; CD38; JNJ- 63723283; denosumab; checkpoint inhibitors; BCMA; bispecific T-cell engager; antibody-drug conjugates
Online: 24 October 2018 (12:11:23 CEST)